Dear Colleagues,

we look forward to meet you at the WSAVA/FECAVA Congress from September 25-28, 2017 in Copenhagen/Denmark.

We will present our data about the immunologic treatment of female dogs with mammary cancer.

A Pilot, Uncontrolled Study of Postsurgical Treatment with Autologous Dendritic Cell-Based Immunologic Therapy in 17 dogs with mammary adenocarcionoma

is the headline of our poster presented at the conference.

Post conference, you will receive the information of the poster via e-mail. Today, we want to emphasize the following important findings:

• The immunologic treatment with dendritic cells in direct connection with the surgical excision of an adenocarcinoma of the mamma is an important therapeutic option to avoid metastatic disease in affected dogs. We present interesting long-time observations regarding the quality of life and survival time.
• It is important to start an immunologic treatment immediately after the surgical intervention and the (malign) patho-histological diagnosis.
• Dogs, which cannot undergo a surgical treatment because of their age, underlying other severe organ diseases or tumor size should definitely start an immunologic treatment with dendritic cell vaccines to achieve a shrinking of the tumor tissue and an improvement of the clinical situation and symptoms.

We look forward to meet you in Copenhagen, here you find the Link to the congress-website: http://www.wsava2017.com/

Dr. Thomas Grammel